We proposed a method for scoring the deleteriousness of mutated genes and identified differentially mutated genes (DMGs) and SNVs from five breast cancer comparison classes (ER+ vs. ER-, PR+ vs. PR-, HER2+ vs. HER2-, grade II vs. grade III, and stage II vs. stage III). This evidence concerns the gene ESR1 and breast carcinoma.